Sfoglia per Autore
Long-Term Effects of Rituximab in Rheumatoid Arthritis Clinical, Biologic, and Pharmacogenetic Aspects
2009-01-01 Quartuccio, Luca; Lombardi, S; Fabris, M; Masolini, P; Saracco, M; Pellerito, R; DE VITA, Salvatore
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis
2009-01-01 Atzeni, F; Benucci, M; Cimmino, M; Cutolo, M; DE VITA, Salvatore; Fabris, Martina; Masolini, Paola; Morassi, P; Pellerito, R; Quartuccio, Luca; Salvin, Sara; Saracco, M; SARZI PUTTINI, P.
B-lymphocyte stimulator and a proliferation-inducing ligand serum levels in IgA-deficient patients with and without celiac disease
2009-01-01 Fabris, M.; De Vita, S.; Visentini, D.; Fabro, C.; Picierno, A.; Lerussi, A.; Villalta, D.; Alessio, M. G.; Tampoia, M.; Tonutti, E.
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis
2009-01-01 Quartuccio, Luca; Salvin, S; Saracco, M; Lombardi, S; Fabris, M; Mansutti, E; Maset, M; Pellerito, S; DE VITA, Salvatore
BLyS and April serum levels in patients with autoimmune thyroid diseases.
2010-01-01 Fabris, M; Grimaldi, F; Villalta, D; Picierno, A; Fabro, C; Bolzan, M; DE VITA, Salvatore; Tonutti, E.
Serum levels of anti-CPP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab
2010-01-01 Fabris, Martina; DE VITA, Salvatore; Blasone, Nadia; Visentini, Daniela; Pezzarini, Elena; Pontarini, Elena; Fabro, Cinzia; Quartuccio, Luca; Mazzolini, Saulle; Curcio, Francesco; Tonutti, Elio
Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis
2010-01-01 Fabris, M; Quartuccio, Luca; Lombardi, S; Benucci, M; Manfredi, M; Saracco, M; Atzeni, F; Morassi, P; Cimmino, Ma; Pontarini, E; Fabro, C; Pellerito, R; Sarzi Puttini, P; Cutolo, M; Carletto, A; Bambara, Lm; Fischetti, F; Curcio, Francesco; Tonutti, E; DE VITA, Salvatore
The role of B-lymphocyte stimulator in neuroendocrine tumors: Correlation with tumor differentiation, disease status and the presence of metastases
2011-01-01 Fabris, M; Tonutti, E; Panighel, C; Blasone, N; Visentini, D; Pizzolitto, S; De Maglio, G; Isola, Miriam; Curcio, Francesco; Grimaldi, F.
Chlamydophila psittaci subclinical infection in chronic polyarthritis
2011-01-01 Fabris, M.; DE VITA, Salvatore; Pasini, E.; Quartuccio, Luca; Pontarini, E.; Lombardi, S.; Fabro, C.; Sarzi Puttini, P.; Pellerito, R.; Belucci, M.; Morassi, P.; Biasi, D.; Curcio, Francesco; Dolcetti, R.
Efficacy of Belimumab On Non-Malignant Parotid Swelling and Systemic Manifestations of Sjo¨gren’s Syndrome: Results of the Beliss Study.
2012-01-01 DE VITA, Salvatore; le Seror, R; Quartuccio, Luca; Desmoulins, F; Salvin, S; Baron, G; Fabris, Martina; Ravaud, P; Isola, Miriam; Mariette, X.
Cryoglobulinaemia related to Sjogren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy.
2012-01-01 DE VITA, Salvatore; Quartuccio, Luca; S., Salvin; L., Corazza; A., Zabotti; M., Fabris
Detection of DNA of Chlamydophila psittaci in subjects with psoriasis: a casual or a causal link?
2012-01-01 Stinco, Giuseppe; Fabris, M; Pasini, E; Pontarini, E; Patriarca, Mm; Piccirillo, F; DE VITA, Salvatore; Dolcetti, R.
Role e of oral cyclophosphamide in the treatment of giant cell arteritis
2012-01-01 Quartuccio, L; Maset, M; De Maglio, G; Pontarini, E; Fabris, M; Mansutti, E.; Mariuzzi, L; Pizzolitto, S; Beltrami, Ca; De Vita, S
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis
2012-01-01 Fabris, M; Quartuccio, Luca; Lombardi, S; Saracco, M; Atzeni, F; Carletto, A; Cimmino, M; Fabro, C; Pontarini, E; Pellerito, R; Bambara, Lm; SARZI PUTTINI, P; Cutolo, M; Manfredi, M; Benucci, M; Morassi, P; Fischetti, F; Padovan, M; Govoni, M; Curcio, Francesco; Tonutti, E; DE VITA, Salvatore
Cost saving and predictive factors of response to rituximab in rheumatoid arthritis, including the IL-6 promoter gene polymorphism
2012-01-01 Quartuccio, Luca; Salvin, S; Fabris, M; Benucci, M; Pellerito, R; Furian, C; Masolini, P; Cimmino, M; Troncon, M. G.; Guarrera, G. M.; DE VITA, Salvatore
BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands
2013-01-01 Quartuccio, Luca; Salvin, S.; Fabris, M.; Maset, M.; Pontarini, E.; Isola, Miriam; DE VITA, Salvatore
Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome.
2013-01-01 Tobón, Gj; Saraux, A; Gottenberg, Je; Quartuccio, Luca; Fabris, M; Seror, R; Devauchelle Pensec, V; Morel, J; Rist, S; Mariette, X; DE VITA, Salvatore; Youinou, P; Pers, J. O.
Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study.
2013-01-01 Mariette, X; Seror, R; Quartuccio, Luca; Baron, G; Salvin, S; Fabris, M; Desmoulins, F; Nocturne, G; Ravaud, P; DE VITA, Salvatore
The TTTT BLyS promoter haplotype associates with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to TNF blockers.
2013-01-01 Fabris, M; Quartuccio, Luca; Vital, E; Pontarini, E; Salvin, S; Fabro, C; Zabotti, A; Benucci, M; Manfredi, M; Ravagnani, V; Biasi, D; Atzeni, F; Sarzi Puttini, P; Morassi, P; Fischetti, F; Bazzicchi, L; Saracco, M; Pellerito, R; Cimmino, M; Carraro, V; Semeraro, A; Schiavon, F; Caporali, R; Bortolotti, R; Govoni, M; Fogolari, Federico; Tonutti, E; Bombardieri, S; Emery, P; DE VITA, Salvatore
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
2014-01-01 Quartuccio, Luca; Fabris, M; Pontarini, E; Salvin, S; Zabotti, A; Benucci, M; Manfredi, M; Biasi, D; Ravagnani, V; Atzeni, F; Sarzi Puttini, P; Morassi, P; Fischetti, F; Tomietto, P; Bazzichi, L; Saracco, M; Pellerito, R; Cimmino, M; Schiavon, F; Carraro, V; Semeraro, A; Caporali, R; Cavagna, L; Bortolotti, R; Paolazzi, G; Govoni, M; Bombardieri, S; DE VITA, Salvatore
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Long-Term Effects of Rituximab in Rheumatoid Arthritis Clinical, Biologic, and Pharmacogenetic Aspects | 1-gen-2009 | Quartuccio, Luca; Lombardi, S; Fabris, M; Masolini, P; Saracco, M; Pellerito, R; DE VITA, Salvatore | |
| Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis | 1-gen-2009 | Atzeni, F; Benucci, M; Cimmino, M; Cutolo, M; DE VITA, Salvatore; Fabris, Martina; Masolini, Paola; Morassi, P; Pellerito, R; Quartuccio, Luca; Salvin, Sara; Saracco, M; SARZI PUTTINI, P. | |
| B-lymphocyte stimulator and a proliferation-inducing ligand serum levels in IgA-deficient patients with and without celiac disease | 1-gen-2009 | Fabris, M.; De Vita, S.; Visentini, D.; Fabro, C.; Picierno, A.; Lerussi, A.; Villalta, D.; Alessio, M. G.; Tampoia, M.; Tonutti, E. | |
| Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis | 1-gen-2009 | Quartuccio, Luca; Salvin, S; Saracco, M; Lombardi, S; Fabris, M; Mansutti, E; Maset, M; Pellerito, S; DE VITA, Salvatore | |
| BLyS and April serum levels in patients with autoimmune thyroid diseases. | 1-gen-2010 | Fabris, M; Grimaldi, F; Villalta, D; Picierno, A; Fabro, C; Bolzan, M; DE VITA, Salvatore; Tonutti, E. | |
| Serum levels of anti-CPP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab | 1-gen-2010 | Fabris, Martina; DE VITA, Salvatore; Blasone, Nadia; Visentini, Daniela; Pezzarini, Elena; Pontarini, Elena; Fabro, Cinzia; Quartuccio, Luca; Mazzolini, Saulle; Curcio, Francesco; Tonutti, Elio | |
| Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis | 1-gen-2010 | Fabris, M; Quartuccio, Luca; Lombardi, S; Benucci, M; Manfredi, M; Saracco, M; Atzeni, F; Morassi, P; Cimmino, Ma; Pontarini, E; Fabro, C; Pellerito, R; Sarzi Puttini, P; Cutolo, M; Carletto, A; Bambara, Lm; Fischetti, F; Curcio, Francesco; Tonutti, E; DE VITA, Salvatore | |
| The role of B-lymphocyte stimulator in neuroendocrine tumors: Correlation with tumor differentiation, disease status and the presence of metastases | 1-gen-2011 | Fabris, M; Tonutti, E; Panighel, C; Blasone, N; Visentini, D; Pizzolitto, S; De Maglio, G; Isola, Miriam; Curcio, Francesco; Grimaldi, F. | |
| Chlamydophila psittaci subclinical infection in chronic polyarthritis | 1-gen-2011 | Fabris, M.; DE VITA, Salvatore; Pasini, E.; Quartuccio, Luca; Pontarini, E.; Lombardi, S.; Fabro, C.; Sarzi Puttini, P.; Pellerito, R.; Belucci, M.; Morassi, P.; Biasi, D.; Curcio, Francesco; Dolcetti, R. | |
| Efficacy of Belimumab On Non-Malignant Parotid Swelling and Systemic Manifestations of Sjo¨gren’s Syndrome: Results of the Beliss Study. | 1-gen-2012 | DE VITA, Salvatore; le Seror, R; Quartuccio, Luca; Desmoulins, F; Salvin, S; Baron, G; Fabris, Martina; Ravaud, P; Isola, Miriam; Mariette, X. | |
| Cryoglobulinaemia related to Sjogren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. | 1-gen-2012 | DE VITA, Salvatore; Quartuccio, Luca; S., Salvin; L., Corazza; A., Zabotti; M., Fabris | |
| Detection of DNA of Chlamydophila psittaci in subjects with psoriasis: a casual or a causal link? | 1-gen-2012 | Stinco, Giuseppe; Fabris, M; Pasini, E; Pontarini, E; Patriarca, Mm; Piccirillo, F; DE VITA, Salvatore; Dolcetti, R. | |
| Role e of oral cyclophosphamide in the treatment of giant cell arteritis | 1-gen-2012 | Quartuccio, L; Maset, M; De Maglio, G; Pontarini, E; Fabris, M; Mansutti, E.; Mariuzzi, L; Pizzolitto, S; Beltrami, Ca; De Vita, S | |
| The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis | 1-gen-2012 | Fabris, M; Quartuccio, Luca; Lombardi, S; Saracco, M; Atzeni, F; Carletto, A; Cimmino, M; Fabro, C; Pontarini, E; Pellerito, R; Bambara, Lm; SARZI PUTTINI, P; Cutolo, M; Manfredi, M; Benucci, M; Morassi, P; Fischetti, F; Padovan, M; Govoni, M; Curcio, Francesco; Tonutti, E; DE VITA, Salvatore | |
| Cost saving and predictive factors of response to rituximab in rheumatoid arthritis, including the IL-6 promoter gene polymorphism | 1-gen-2012 | Quartuccio, Luca; Salvin, S; Fabris, M; Benucci, M; Pellerito, R; Furian, C; Masolini, P; Cimmino, M; Troncon, M. G.; Guarrera, G. M.; DE VITA, Salvatore | |
| BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands | 1-gen-2013 | Quartuccio, Luca; Salvin, S.; Fabris, M.; Maset, M.; Pontarini, E.; Isola, Miriam; DE VITA, Salvatore | |
| Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome. | 1-gen-2013 | Tobón, Gj; Saraux, A; Gottenberg, Je; Quartuccio, Luca; Fabris, M; Seror, R; Devauchelle Pensec, V; Morel, J; Rist, S; Mariette, X; DE VITA, Salvatore; Youinou, P; Pers, J. O. | |
| Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. | 1-gen-2013 | Mariette, X; Seror, R; Quartuccio, Luca; Baron, G; Salvin, S; Fabris, M; Desmoulins, F; Nocturne, G; Ravaud, P; DE VITA, Salvatore | |
| The TTTT BLyS promoter haplotype associates with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to TNF blockers. | 1-gen-2013 | Fabris, M; Quartuccio, Luca; Vital, E; Pontarini, E; Salvin, S; Fabro, C; Zabotti, A; Benucci, M; Manfredi, M; Ravagnani, V; Biasi, D; Atzeni, F; Sarzi Puttini, P; Morassi, P; Fischetti, F; Bazzicchi, L; Saracco, M; Pellerito, R; Cimmino, M; Carraro, V; Semeraro, A; Schiavon, F; Caporali, R; Bortolotti, R; Govoni, M; Fogolari, Federico; Tonutti, E; Bombardieri, S; Emery, P; DE VITA, Salvatore | |
| The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. | 1-gen-2014 | Quartuccio, Luca; Fabris, M; Pontarini, E; Salvin, S; Zabotti, A; Benucci, M; Manfredi, M; Biasi, D; Ravagnani, V; Atzeni, F; Sarzi Puttini, P; Morassi, P; Fischetti, F; Tomietto, P; Bazzichi, L; Saracco, M; Pellerito, R; Cimmino, M; Schiavon, F; Carraro, V; Semeraro, A; Caporali, R; Cavagna, L; Bortolotti, R; Paolazzi, G; Govoni, M; Bombardieri, S; DE VITA, Salvatore |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile